European CHMP Adopts Positive Opinion for Cobimetinib in Combination with Vemurafenib for the Treatment of Advanced Melanoma
September 25, 2015 at 07:43 AM EDT
Exelixis, Inc. (NASDAQ: EXEL) today announced that the European Medicines Agency's Committee for Medical Products for Human Use (CHMP) ...